Outcome and long-term results of pancreatic neuroendocrine neoplasms with size more/equal than 4 cm

Pancreatology ◽  
2020 ◽  
Vol 20 ◽  
pp. S112
Author(s):  
A. Milanetto ◽  
A. David ◽  
A. Gais Zürcher ◽  
C. Pasquali
Keyword(s):  
Long Term Results ◽  
Neuroendocrine Neoplasms ◽  
Pancreatic Neuroendocrine Neoplasms

Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1

2011 ◽  
Vol 396 (8) ◽  
pp. 1187-1196 ◽  
Author(s):  
Caroline L. Lopez ◽  
Jens Waldmann ◽  
Volker Fendrich ◽  
Peter Langer ◽  
Peter H. Kann ◽  
...  
Keyword(s):  
Long Term Results ◽  
Neuroendocrine Neoplasms ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Results Of Surgery

scholarly journals Short- and long-term outcomes of laparoscopic organ-sparing resection for pancreatic neuroendocrine neoplasms

2020 ◽  
Author(s):  
Ren-Chao Zhang ◽  
Jun Ma ◽  
yiping mou ◽  
Yu-Cheng Zhou ◽  
Wei-Wei Jin ◽  
...  
Keyword(s):  
Distal Pancreatectomy ◽  
Neuroendocrine Neoplasms ◽  
Transfusion Rate ◽  
Long Term Outcomes ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Spleen Preserving ◽  
Short And Long Term ◽  
Organ Sparing

Abstract Background：Pancreatic neuroendocrine neoplasms (PNENs) are rare neoplasms associated with a long life expectancy after resection. In this setting, patients may benefit from laparoscopic organ-sparing resection. Studies of laparoscopic organ-sparing resection for PNENs are limited. The aim of this study was to evaluate the short- and long-term outcomes of laparoscopic organ-sparing resection for PNENs.Methods： A retrospective study was performed for patients with PNENs who underwent laparoscopic organ-sparing pancreatectomy between March 2005 and May 2018. The patients’ demographic data, operative results, pathological reports, hospital courses and morbidity, mortality, and follow-up data (until August 2018) were analysed.Results：Thirty-five patients were included in the final analysis. There were 9 male and 26 female patients, with a median age of 46 years (range, 25-75 years). The mean BMI was 24.6±3.3 kg/m2. Nine patients received laparoscopic enucleation (LE), 20 received laparoscopic spleen-preserving distal pancreatectomy (LSPDP), and 6 received laparoscopic central pancreatectomy. The operative time, intraoperative blood loss, transfusion rate, and postoperative hospital stay were 186.4±60.2 min, 165±73.0 ml, 0 d, and 9 d (range, 5-23 d), respectively. The morbidity rate, grade ≥III complication rate and grade ≥B pancreatic fistula rate were 34.2%, 11.4%, and 8.7%, respectively, with no mortality. The rate of follow-up was 94.3%, and the median follow-up time was 55 months (range, 3-158 months). One patient developed recurrence 36 months after LE and was managed with surgical resection. The other patients survived without metastases or recurrence during the follow-up. One patient had diabetes after laparoscopic spleen-preserving distal pancreatectomy, and no patients had symptoms of pancreatic exocrine insufficiency. Conclusions： Laparoscopic organ-sparing resection for selected cases of PNENs is safe and feasible and has favourable short- and long-term outcomes.

Features of clinical course, morphological diagnosis and prognosis factors for neuroendocrine neoplasms of rare localizations

2020 ◽  
pp. 54-60
Author(s):  
D. V. Abbasova ◽  
S. B. Polikarpova ◽  
N. A. Kozlov ◽  
Ye. V. Artamonova ◽  
V. Yu. Kirsanov ◽  
...  
Keyword(s):  
Prostate Gland ◽  
Survival Rates ◽  
Long Term Results ◽  
Neuroendocrine Neoplasms ◽  
High Survival ◽  
Diagnosis And Prognosis ◽  
National Medical ◽  
Static Data ◽  
Morphological Diagnosis

Currently, neuroendocrine neoplasms (NENs) of the gastroenteropancreat-ic and bronchopulmonary systems are well studied and the most common, the share of which is 73 and 25 % of cases, respectively. The remaining 2 % of cases are attributed to NEN of more rare localizations, the static registration of which is difficult due to their rarity, and clinical cases are presented by episodic descriptions of single observations. Such tumors include NEN of the prostate gland from 0.5 to 1.0 %, NEN of ovaries 0.5 %, NEN of the mammary gland from 0.3 to 0.5 %, NEN of the kidney (practically devoid of static data), bladder 0.48-1.00 %. The retrospective study included 92 patients with NEN of rare localizations who were examined and treated of the N. N. Blochin National Medical Research Center of Oncology from 1990 to 2019. Currently, there are no generally accepted methods of treatment for this group of patients due to the rarity of the pathology, and it is carried out according to the NEN of other localizations. NEN of rare localizations have high survival rates (the observation period was from a month to 14 years), both general and without progression and require long-term monitoring and observation. At the time of assessment of long-term results, 20 (21.8 %) patients died of progression, 12 (13.1 %) patients dropped out of observation. The rest were alive at the date of the last control.

VHL-RELATED NEUROENDOCRINE NEOPLASMS AND BEYOND: AN ISRAELI SPECIALIZED CENTER REAL-LIFE REPORT

2020 ◽  
Vol 26 (10) ◽  
pp. 1131-1142
Author(s):  
Auryan Szalat ◽  
Kira Oleinikov ◽  
Avital Nahmias ◽  
Vardiella Meiner ◽  
Simona Ben-Haim ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Neuroendocrine Tumor ◽  
Neuroendocrine Neoplasms ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Von Hippel Lindau ◽  
Mutation Carriers ◽  
Long Term Follow Up

Objective: Von Hippel-Lindau (VHL) syndrome is a rare and complex disease. In 1996, we described a 3 generation VHL 2A kindred with 11 mutation carriers. We aim to share our experience regarding the long-term follow-up of this family and the management of all our other VHL patients focusing on frequently encountered neuroendocrine neoplasms: pheochromocytoma/paraganglioma and pancreatic neuroendocrine neoplasms (PNEN). Methods: All VHL patients in follow-up at our tertiary center from 1980 to 2019 were identified. Clinical, laboratory, imaging, and therapeutic characteristics were retrospectively analyzed. Results: We identified 32 VHL patients in 16 different families, 7/16 were classified as VHL 2 subtype. In the previously described family, the 4 initially asymptomatic carriers developed a neuroendocrine tumor; 7 new children were born, 3 of them being mutation carriers; 2 patients died, 1 due to metastatic PNEN-related liver failure. Pheochromocytoma was frequent (22/32), bilateral (13/22;59%), often diagnosed in early childhood when active screening was timely performed, associated with paraganglioma in 5/22, rarely malignant (1/22), and recurred after surgery in some cases after more than 20 years. PNEN occurred in 8/32 patients (25%), and was metastatic in 3 patients. Surgery and palliative therapy allowed relatively satisfactory outcomes. Severe disabling morbidities due to central-nervous system and ophthalmologic hemangiomas, and other rare tumors as chondrosarcoma in 2 patients and polycythemia in 1 patient were observed. Conclusion: A multidisciplinary approach and long-term follow-up is mandatory in VHL patients to manage the multiple debilitating morbidities and delay mortality in these complex patients. Abbreviations: CNS = central nervous system; HIF = hypoxia inducible factor; PGL = paraganglioma; PHD = prolyl hydroxylase; Pheo = pheochromocytoma; PNEN = pancreatic neuroendocrine neoplasms; PNET = pancreatic neuroendocrine tumor; RCC = clear cell renal cell carcinoma; VHL = Von Hippel-Lindau

Long-term outcomes in MEN-1 patients with pancreatic neuroendocrine neoplasms: an Israeli specialist center experience

Endocrine ◽  
2020 ◽  
Vol 68 (1) ◽  
pp. 222-229
Author(s):  
Kira Oleinikov ◽  
Inbal Uri ◽  
Harold Jacob ◽  
Julia Epshtein ◽  
Ariel Benson ◽  
...  
Keyword(s):  
Neuroendocrine Neoplasms ◽  
Long Term Outcomes ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Men 1 ◽  
Specialist Center

scholarly journals Total Pancreatectomy with Autologous Islet Cell Transplantation—The Current Indications

2021 ◽  
Vol 10 (12) ◽  
pp. 2723
Author(s):  
Beata Jabłońska ◽  
Sławomir Mrowiec
Keyword(s):  
Total Pancreatectomy ◽  
Long Term Results ◽  
Pancreatic Tumors ◽  
Neuroendocrine Neoplasms ◽  
Islet Cell Transplantation ◽  
Pancreatic Stump ◽  
Primary Indication ◽  
Autologous Islet Transplantation ◽  
Endocrine Insufficiency

Total pancreatectomy is a major complex surgical procedure involving removal of the whole pancreatic parenchyma and duodenum. It leads to lifelong pancreatic exocrine and endocrine insufficiency. The control of surgery-induced diabetes (type 3) requires insulin therapy. Total pancreatectomy with autologous islet transplantation (TPAIT) is performed in order to prevent postoperative diabetes and its serious complications. It is very important whether it is safe and beneficial for patients in terms of postoperative morbidity and mortality, and long-term results including quality of life. Small duct painful chronic pancreatitis (CP) is a primary indication for TPAIT, but currently the indications for this procedure have been extended. They also include hereditary/genetic pancreatitis (HGP), as well as less frequent indications such as benign/borderline pancreatic tumors (intraductal papillary neoplasms, neuroendocrine neoplasms) and “high-risk pancreatic stump”. The use of TPAIT in malignant pancreatic and peripancreatic neoplasms has been reported in the worldwide literature but currently is not a standard but rather a controversial management in these patients. In this review, history, technique, indications, and contraindications, as well as short-term and long-term results of TPAIT, including pediatric patients, are described.

scholarly journals Short- and long-term outcomes of laparoscopic organ-sparing resection for pancreatic neuroendocrine neoplasms

2020 ◽  
Author(s):  
Renchao Zhang ◽  
Jun Ma ◽  
Yi-Ping Mou ◽  
Yu-Cheng Zhou ◽  
Wei-Wei Jin ◽  
...  
Keyword(s):  
Distal Pancreatectomy ◽  
Neuroendocrine Neoplasms ◽  
Long Term Outcomes ◽  
Pancreatic Neuroendocrine Neoplasms ◽  
Spleen Preserving ◽  
Short And Long Term ◽  
Organ Sparing ◽  
Laparoscopic Enucleation

Abstract BackgroundPancreatic neuroendocrine neoplasms (PNENs) are rare neoplasm with long life expectancy. In this setting, patients may benefit from laparoscopic organ-sparing resection. There are few reports of laparoscopic organ-sparing resection for PNENs. The aim of this study was to evaluate the Short- and long-term outcomes of laparoscopic organ-sparing resection for PNENs.MethodsA retrospective study was performed for patients with PNENs who underwent laparoscopic organ-sparing pancreatectomy between March 2005 and May 2018. The patients’ demographic data, operative results, pathological reports, hospital courses, morbidity and mortality, and follow-up data (including pancreatic function, till August 2018) was analyzed.ResultsThirty-five patients were identified. There were 9 male and 26 female patients, with a median age of 46 years (range, 25-75 years). The mean BMI was 24.6±3.3kg/m2. Nine patients received laparoscopic enucleation, 20 received laparoscopic spleen-preserving distal pancreatectomy, and 6 received laparoscopic central pancreatectomy. The operative time, intraoperative blood loss, transfusion rate, postoperative hospital stay were 186.4±60.2min, 165±73.0ml, 0, 9d(range, 5-23d), respectively. The morbidity rate, ≥Grade Ⅲ complication rate and ≥grade B pancreatic fistula rate were 34.2%, 11.4%, 8.7%, respectively, with no mortality. The rate of follow-up was 94.3%, and the median follow-up time was 55 months (range, 3-158months). One patients had diabetes after laparoscopic spleen-preserving distal pancreatectomy, no patient had symptom of pancreatic exocrine insufficiency. One patient developed recurrence 36 months after laparoscopic enucleation and was managed with surgical resection. The other patients survived without metastases or recurrence during the follow-up.ConclusionsLaparoscopic organ-sparing resection for selected cases of PNENs is safe and feasible, and have favorable short- and long-term outcome.

Sign in / Sign up

Export Citation Format

Share Document